EP0155288A1 - Implant biodegradable - Google Patents

Implant biodegradable

Info

Publication number
EP0155288A1
EP0155288A1 EP84903286A EP84903286A EP0155288A1 EP 0155288 A1 EP0155288 A1 EP 0155288A1 EP 84903286 A EP84903286 A EP 84903286A EP 84903286 A EP84903286 A EP 84903286A EP 0155288 A1 EP0155288 A1 EP 0155288A1
Authority
EP
European Patent Office
Prior art keywords
glass
implant
slurry
minutes
foaming agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP84903286A
Other languages
German (de)
English (en)
Inventor
Laslo The University of Strathclyde JUHASZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Strathclyde
Original Assignee
University of Strathclyde
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Strathclyde filed Critical University of Strathclyde
Publication of EP0155288A1 publication Critical patent/EP0155288A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C03—GLASS; MINERAL OR SLAG WOOL
    • C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
    • C03C3/00—Glass compositions
    • C03C3/12—Silica-free oxide glass compositions
    • C03C3/16—Silica-free oxide glass compositions containing phosphorus
    • C03C3/17—Silica-free oxide glass compositions containing phosphorus containing aluminium or beryllium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/28—Bones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/12—Phosphorus-containing materials, e.g. apatite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • C—CHEMISTRY; METALLURGY
    • C03—GLASS; MINERAL OR SLAG WOOL
    • C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
    • C03C4/00—Compositions for glass with special properties
    • C03C4/0035—Compositions for glass with special properties for soluble glass for controlled release of a compound incorporated in said glass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005—The prosthesis being constructed from a particular material
    • A61F2310/00179—Ceramics or ceramic-like structures
    • A61F2310/00293—Ceramics or ceramic-like structures containing a phosphorus-containing compound, e.g. apatite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • A61L2300/104—Silver, e.g. silver sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A61L2300/604—Biodegradation

Definitions

  • This invention relates to a biodegradable implant for human or animal use.
  • An object of the present invention is to provide a biodegradable implant which will dissolve in body fluids at a predeterminable rate.
  • a biodegradable implant of which the material of manu ⁇ facture is a biodegradable glass comprising a glass- forming or modifying component and a biocompatible metal oxide in which the ratio of the metallic elements in the glass are in substantially the same ratio as in the tissue in contact with which the implant is to be located.
  • the glass also contains an amount of a physiologically benign processing additive and/or a chemotherapeutic agent.
  • the chemotherapeutic agent may be, for example, a free metal selected from zinc, copper, silver, gold and platinum and mixtures thereof, preferably in a concen ⁇ tration of from 1 to 10 %.
  • the glass-forming/modifying component is phosphorus pentoxide and alumina and the ratio of glass- former to metal oxide in the glass is from 1:3 to 3:1.
  • the glass preferably contains no more than five mole percent of alumina.
  • the glass may be produced by fusion in the presence of an amount of a gas-releasing foaming agent such as an inorganic carbonate or bicarbonate.
  • the implant may be produced by casting of the glass in the molten state in a mould or by machining a body of the glass using ordinary techniques.
  • the glass When the glass is produced by fusion of a mixture of the powdered components in a platinum crucible under an inert atmosphere the fusion occurs at around 1100 to 1300°C.
  • the melt may be cast bypouring into moulds, extrusion to give tubes, ground to a powder or formed into beads. Conventional glass fabrication and hand ⁇ ling techniques are applicable. Powdered glass may be further processed to produce other forms, for example, as follows:
  • a sintered glass may be made by forming glass pow ⁇ der into a slurry with liquid, normally water, and subjecting the slurry to pressure and heat to form a compact mass. This step may conveniently be done at a pressure of from 5 to 20 tons and a tem ⁇ perature of around 350°C for 10 to 30 minutes. The compact mass is then fired in a furnace at a temperature of from 700 to 900°C for from 5 to 10 minutes.
  • the glass so produced may have a tensile strength of from 20 to 40 MPa and a compression of from 200 to 400 MPa. It is useful as a bone substitute: real bone has a tensile strength of around 196 MPa. 2.
  • a propor- tion of a foaming agent that is a substance which liberates gas at the fusion temperature and may be, for example, calcium or sodium carbonate, a glass may be produced in a foamed form.
  • the pore size distribution may be around 100 to 200 microns but can be varied by varying the particle size of the powdered components.
  • a quantity of ground and screened glass is mixed with a quantity (from 0.01 to 2.00 % by weight) of calcium carbonate or other suitable foaming agent in a porcelain crucible or a mould and heated to a temperature to fuse the glass and to liberate the foaming gas.
  • a tempera ⁇ ture of from 600 to 700°C is sufficient.
  • the foamed mass is allowed to cool to give a porous body which can be further fabricated to shape by grinding and milling etc..
  • the foamed glass thus produced is not structurally strong. 3.
  • Porous glass, which has a greater in structural strength than the foamed glass described in the foregoing paragraph may be produced by a modifi ⁇ cation of the foamed glass production process.
  • a mix may be made up as described above but the mix then slurried with water.
  • the foaming agent may be a carbonate as described before or hydrogen peroxide.
  • the slurry is heated at from 100 to 180°C for from 15 to 20 minutes and then placed in a mould or crucible and fired at 600 to 700°C for from 10 to 30 minutes.
  • the porous body so produced has a smaller pore size than the foamed glass (from 10 to 30 microns) and consequently greater strength.
  • the porous glass is also useful as a bone substitute.
  • Inorganic chemotherapeutic agents may be incorporated into the glass simply by fusing them along with the other powder components of the mix.
  • colloidal metals such as zinc, . - copper, silver gold and platinum.
  • the present invention provides a convenient method of delivering them to the affected site in very finely divided form and releasing them from the glass over a long period of time which is deter ⁇ mined by the rate of dissolution of the glass in the body.
  • Fine beads of glass may be formed by conventional glass fabrication techniques and may be directly injected to the affected sites.
  • fine needles of the glass may be inser ⁇ ted through the skin of a patient directly to the site.
  • One advantage of this technique is that the progress of the needle into the body may be mon ⁇ itored very easily under X-ray, since all the glasses are radio-opaque.
  • Ground powders or fine beads of the glass provide a convenient form for direct topical application to wound management when therapeutic metals are used.
  • the bone substitutes of this invention are of par ⁇ ticular importance. Particular examples of the use are: (a) delayed and non-union fractures,
  • Moulded biodegradable glass having a typical composition: 44% phosphorus pentoxide, 18% sodium oxide, 1% alumina, the remainder being calcium oxide, is used as a spacer or joint resurfacer in surgery on arthritic joints.
  • Patients suffering from rheumatoid arthritis of the hand in whom the disease has progressed to the extent of des ⁇ truction of the articular cartilage but not to disrup ⁇ tion of the joint or bone erosion, may be treated by re ⁇ construction of the cartilage by means of a perichondral graft.
  • the two articular surfaces covered by the graft have to be physically separated for a period of from four to six weeks.
  • _QMPI may create major problems.
  • Resurfacing of the hip joint with biodegradable glass provides a biological solution for young patients by facilitating regeneration and repair of the cartilage surface. It will direct the replacement of damaged ar ⁇ ticular surface cartilage, permit early post-operative motion and protect young cartilage cells until a stable matrix is formed by " these cells. After a period of time this temporary glass prosthesis will completely dissolve away and provide a functional joint surface.
  • Example 2
  • a typical glass composition for these purposes is: 30% phosphorus pentoxide, 4.8% potassium oxide, 3.6% zinc oxide and 1% alumina, the remainder being sodium oxide. This dissolution time is around two to three weeks.
  • Tubes made of the glasses serve as temporary ducting in various vessels after surgery such as blood vessels, bile duct, ureter and vas deferens. These tubes are inserted into the cut ends of the vessels and the ends are then stitched together around the outside of the tube. As the surgical stitching heals and the vessel ends unite the internal tubing dissolves thus avoiding the need for second surgical intervention as is presently done using silicone rubber shunts.
  • a typical glass for this use has the composition: 44% phosphorus pentoxide, 40% sodium oxide, 1.3% potassium oxide, 1% alumina the re- mainder being calcium oxide.
  • Foamed Biodegradable glass is useful as a bone substitute for treating bone defects as a result of disease or surgery as its porous nature encourages tis- sue growth and acts as dynamic scaffolding.
  • Inorganic ions enhance healing and stimulate bone formation leaving the regenerated natural bone behind.
  • Important areas of application are orthopaedic and craniofacial surgery when it is difficult to obtain sufficient autogenous bone, particularly in veryyoung patients.
  • a typical composition for such uses is: 62% phosphorus pentoxide, 1% alumina, 1.5% sodium oxide the remainder being calcium oxide. Sodium carbonate at a level of 1% is incorporated into the mix prior to fusion to cause the molten glass to foam.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Geochemistry & Mineralogy (AREA)
  • Organic Chemistry (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Un implant biodégradable est fabriqué à partir d'un matériau de verre biodégradable qui contient un matériau de formation de verre et un ou plusieurs oxydes métalliques, le matériau de formation de verre étant du pentoxyde de phosphore et de l'alumine, et un oxyde métallique. Le rapport des éléments métalliques dans le verre est sensiblement le même que celui des tissus dans lesquels doit être implantée la greffe. Cela permet de réduire les chances de rejet de la greffe par le corps. Le verre peut être produit sous la forme d'un corps de mousse pour obtenir un produit de substitution des os.
EP84903286A 1983-09-10 1984-09-10 Implant biodegradable Withdrawn EP0155288A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB838324276A GB8324276D0 (en) 1983-09-10 1983-09-10 Biocompatible glasses
GB8324276 1983-09-10

Publications (1)

Publication Number Publication Date
EP0155288A1 true EP0155288A1 (fr) 1985-09-25

Family

ID=10548598

Family Applications (1)

Application Number Title Priority Date Filing Date
EP84903286A Withdrawn EP0155288A1 (fr) 1983-09-10 1984-09-10 Implant biodegradable

Country Status (3)

Country Link
EP (1) EP0155288A1 (fr)
GB (1) GB8324276D0 (fr)
WO (1) WO1985001210A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6831052B2 (en) 2001-02-01 2004-12-14 Cognis Deutschland Gmbh Cleaning compositions containing hydroxy mixed ethers, methods of preparing the same, and uses therefor
US6897193B2 (en) * 2001-12-22 2005-05-24 Cognis Deutschland Gmbh & Co., Kg Hydroxy mixed ethers and polymers in the form of solid preparations as a starting compound for laundry detergents, dishwashing detergents and cleaning compositions

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2178422B (en) * 1985-08-02 1990-02-14 Stc Plc Prosthesis formed from water-soluble phosphate glass.
GB2182034A (en) * 1985-10-23 1987-05-07 Stc Plc Sintered glass
GB8720502D0 (en) * 1987-08-29 1987-10-07 Giltech Ltd Antimicrobial composition
DK0455706T3 (da) * 1989-01-27 1997-10-13 Giltech Ltd Medicinsk substans til topisk anvendelse.
US5470585A (en) * 1989-01-27 1995-11-28 Giltech Limited Medicinal substance for topical application
US6113640A (en) * 1997-06-11 2000-09-05 Bionx Implants Oy Reconstructive bioabsorbable joint prosthesis
US6692499B2 (en) 1997-07-02 2004-02-17 Linvatec Biomaterials Oy Surgical fastener for tissue treatment
US6210703B1 (en) 1997-12-19 2001-04-03 Ppg Industries Ohio, Inc. Glass fiber chemical delivery system
EP1067873A1 (fr) 1998-04-01 2001-01-17 Bionx Implants Oy Dispositif de fixation chirurgical bioabsorbable utilise dans le traitement des tissus
GB9811663D0 (en) * 1998-06-01 1998-07-29 Giltech Ltd Composition
GB9811661D0 (en) * 1998-06-01 1998-07-29 Giltech Ltd Compositions
AU5485200A (en) * 1999-06-14 2001-01-02 Imperial College Innovations Silver-containing, sol-gel derived bioglass compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH613679A5 (en) * 1973-05-23 1979-10-15 Leitz Ernst Gmbh Glass-ceramic material, and process for the production thereof
GB1487181A (en) * 1974-10-30 1977-09-28 Colgate Palmolive Co Sintered ceramics
DE2807132C2 (de) * 1978-02-20 1983-11-03 Battelle-Institut E.V., 6000 Frankfurt Implantierbares Pharmaka-Depot
US4308064A (en) * 1978-10-19 1981-12-29 Ngk Spark Plugs Co., Ltd. Phosphate of calcium ceramics
WO1981002667A1 (fr) * 1980-03-27 1981-10-01 Nat Res Dev Implants chirurgicaux antimicrobiens
IE52687B1 (en) * 1980-03-27 1988-01-20 Nat Res Dev Orthopaedic implants
EP0061108B1 (fr) * 1981-03-19 1986-12-30 mundipharma GmbH Article à être implanté dans l'os, procédé pour sa fabrication et son utilisation
GB2099702B (en) * 1981-06-04 1984-08-08 Standard Telephones Cables Ltd Water-soluble prosthesis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8501210A1 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6831052B2 (en) 2001-02-01 2004-12-14 Cognis Deutschland Gmbh Cleaning compositions containing hydroxy mixed ethers, methods of preparing the same, and uses therefor
US6897193B2 (en) * 2001-12-22 2005-05-24 Cognis Deutschland Gmbh & Co., Kg Hydroxy mixed ethers and polymers in the form of solid preparations as a starting compound for laundry detergents, dishwashing detergents and cleaning compositions

Also Published As

Publication number Publication date
WO1985001210A1 (fr) 1985-03-28
GB8324276D0 (en) 1983-10-12

Similar Documents

Publication Publication Date Title
CN101018573B (zh) 一种多孔的晶体或部分晶体合成物及其制备方法
时东陆 Biomaterials and tissue engineering
US5064436A (en) Bone prosthetic material
Vogel et al. The development of bioglass ceramics for medical applications
WO1985001210A1 (fr) Implant biodegradable
US3981736A (en) Biocompatible glass ceramic material
Workie et al. A study of bioactive glass–ceramic's mechanical properties, apatite formation, and medical applications
Agathopoulos et al. The fluorapatite–anorthite system in biomedicine
JPS63125259A (ja) リン酸カルシウム系多孔質骨補填材
WO1996000536A1 (fr) Particules bioactives destinees a la formation de tissu osseux
JPS60166247A (ja) 燐酸塩ガラスセラミツク材料
Turner Ceramics and glasses
Boccardi et al. Bioactive glass-ceramic scaffolds: Processing and properties
AU2015268878A1 (en) Compositions and methods for regeneration of hard tissues
RU2053737C1 (ru) Биоактивный микропористый материал для костной хирургии и способ его изготовления
US10524916B2 (en) Resorbable macroporous bioactive glass scaffold and method of manufacture
Greish et al. Characterization of bioactive glass–reinforced HAP–polymer composites
WO1993017976A1 (fr) Verre bioactif utilise comme substitut osseux
Dias et al. In vivo performance of biodegradable calcium phosphate glass ceramics using the rabbit model: histological and SEM observation
Swain et al. Bioceramic coating for tissue engineering applications
Vlasov et al. Ceramics and medicine
KR20090077650A (ko) 생체활성 유리 조성물 및 이를 이용한 결정화 유리의제조방법
JPS59146658A (ja) 生物反応性材料
CN115554468A (zh) 含生物活性玻璃的骨水泥及其制备方法和应用
Lin et al. The bonding behavior of DP-Bioglass and bone tissue

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19850813

RIN1 Information on inventor provided before grant (corrected)

Inventor name: JUHASZ, LASLOTHE UNIVERSITY OF STRATHCLYDE